-
-
-
-
-
-
-
Karyopharm completes endometrial cancer trial enrollment, reports Q1 results
-
-
-
-
-
-
-
Karyopharm to Report Third Quarter 2025 Financial Results on November 3, 2025
-
-
-
-
-
-
-
Karyopharm Reports First Quarter 2025 Financial Results and Announces New Data in Myelofibrosis that Further Suggests Selinexor May Lead to Meaningful Spleen Volume Reduction, Symptom Improvement, Hem
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) Reports In-Line Q3 EPS ; Offers Guidance
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) Announces Significant Refinancing Transactions and Amended Royalty Agreement Extending Vast Majority of Its Debt Maturities into 2028 and 2029
-
-
-
-
-
-
-
Karyopharm Therapeutics (KPTI) Misses Q3 EPS by 2c
-
-
-
-
-
-
-
Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
-
1,223,532 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

